SuperworthCEL SCI EPS CVM
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$2.69
- Latest quarter, Q3 FY26
- −$0.47
- Fiscal year 2025
- −$7.81
CEL SCI's earnings per share was −$2.69 over the twelve months to Jun 30, 2026.
In its latest quarter, Q3 FY26, it was −$0.47.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$7.81 | n/a |
| FY2024 | −$15.55 | n/a |
| FY2023 | −$21.60 | n/a |
| FY2022 | −$26.10 | n/a |
| FY2021 | −$27.90 | n/a |
| FY2020 | −$24.60 | n/a |
| FY2019 | −$21.30 | n/a |
| FY2018 | −$54.30 | n/a |
| FY2017 | −$56.10 | n/a |
| FY2016 | −$69.90 | n/a |
| FY2015 | −$351.60 | n/a |
| FY2014 | −$472.50 | n/a |
| FY2013 | −$495.00 | n/a |
| FY2012 | −$675.00 | n/a |
| FY2011 | −$1125.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | −$0.47 | n/a | −$2.69 | |
| Q2 FY26 | −$0.67 | n/a | −$3.58 | |
| Q1 FY26 | −$0.68 | n/a | −$5.24 | |
| Q4 FY25 | −$0.87 | n/a | −$7.81 | |
| Q3 FY25 | −$1.36 | n/a | −$9.91 | |
| Q2 FY25 | −$2.33 | n/a | −$12.73 | |
| Q1 FY25 | −$3.25 | n/a | −$14.60 | |
| Q4 FY24 | −$2.97 | n/a | −$15.55 | |
| Q3 FY24 | −$4.18 | n/a | −$17.38 | |
| Q2 FY24 | −$4.20 | n/a | −$18.90 | |
| Q1 FY24 | −$4.20 | n/a | −$20.40 | |
| Q4 FY23 | −$4.80 | n/a | −$21.60 |
Against its peers
Companies in Healthcare nearest CEL SCI's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CVMCEL SCI | −$2.69 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CEL SCI
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.